AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Incannex Healthcare Limited American Depositary Shares
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01J0814Z1
2.64▲ 0.04 (1.54%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
2.60
Day's Range
2.57 – 2.69
52-Week Range
0.15 – 6.91
Volume
38.0K
Avg Volume
82.9K
Share Statistics
Shares Outstanding
Employees
12
Exchange
XNAS
Listed
2022-02-25
Share count as of September 24, 2026

Incannex Healthcare Limited American Depositary Shares (IXHL) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Incannex Healthcare Limited American Depositary Shares (IXHL)
What is Incannex Healthcare Limited American Depositary Shares's Market Cap?
Incannex Healthcare Limited American Depositary Shares's Market Cap is $33.1M, based on as-reported figures from SEC (XBRL) filings.
What is Incannex Healthcare Limited American Depositary Shares's Revenue (TTM)?
Incannex Healthcare Limited American Depositary Shares's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Incannex Healthcare Limited American Depositary Shares's Net Income (TTM)?
Incannex Healthcare Limited American Depositary Shares's Net Income (TTM) is -$19.3M, based on as-reported figures from SEC (XBRL) filings.
What is Incannex Healthcare Limited American Depositary Shares's EBITDA?
Incannex Healthcare Limited American Depositary Shares's EBITDA is -$22.8M, based on as-reported figures from SEC (XBRL) filings.
What is Incannex Healthcare Limited American Depositary Shares's Diluted EPS (TTM)?
Incannex Healthcare Limited American Depositary Shares's Diluted EPS (TTM) is -1.54, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · IXHLAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
Revenue from customers————
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue————
Loss from operations
% of revenue————
Other income, net:
R&D tax incentive
Foreign exchange gains/(losses)
Interest expense————
Interest income
Change in fair value of convertible rights————
Change in fair value of warrant liabilities——
Warrant issuance costs——
Loss on extinguishment————
ELOC commitment fee————
Share of earnings (loss) of joint venture
Total other income/(expenses), net
Loss before income tax expense
Net loss
% of revenue————
Net loss per share: Basic (in USD per share)—
Net loss per share: diluted (in USD per share)—